JP5550339B2 - シクレソニドを含有する無菌性水性懸濁液 - Google Patents
シクレソニドを含有する無菌性水性懸濁液 Download PDFInfo
- Publication number
- JP5550339B2 JP5550339B2 JP2009525822A JP2009525822A JP5550339B2 JP 5550339 B2 JP5550339 B2 JP 5550339B2 JP 2009525822 A JP2009525822 A JP 2009525822A JP 2009525822 A JP2009525822 A JP 2009525822A JP 5550339 B2 JP5550339 B2 JP 5550339B2
- Authority
- JP
- Japan
- Prior art keywords
- aqueous suspension
- microgel
- ciclesonide
- water
- sterile aqueous
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- LUKZNWIVRBCLON-GXOBDPJESA-N Ciclesonide Chemical compound C1([C@H]2O[C@@]3([C@H](O2)C[C@@H]2[C@@]3(C[C@H](O)[C@@H]3[C@@]4(C)C=CC(=O)C=C4CC[C@H]32)C)C(=O)COC(=O)C(C)C)CCCCC1 LUKZNWIVRBCLON-GXOBDPJESA-N 0.000 title claims description 44
- 229960003728 ciclesonide Drugs 0.000 title claims description 41
- 239000007900 aqueous suspension Substances 0.000 title claims description 38
- 229920000831 ionic polymer Polymers 0.000 claims description 27
- 239000003814 drug Substances 0.000 claims description 18
- 230000001954 sterilising effect Effects 0.000 claims description 17
- 229920003169 water-soluble polymer Polymers 0.000 claims description 16
- 238000001914 filtration Methods 0.000 claims description 14
- 229920002148 Gellan gum Polymers 0.000 claims description 10
- 235000010492 gellan gum Nutrition 0.000 claims description 10
- 239000000216 gellan gum Substances 0.000 claims description 10
- 150000002500 ions Chemical class 0.000 claims description 8
- 150000001875 compounds Chemical class 0.000 claims description 6
- -1 cyclohexylmethylene Chemical group 0.000 claims description 6
- 238000004519 manufacturing process Methods 0.000 claims description 6
- 238000002156 mixing Methods 0.000 claims description 6
- 229920001817 Agar Polymers 0.000 claims description 5
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 claims description 5
- 108010010803 Gelatin Proteins 0.000 claims description 5
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims description 5
- 239000008272 agar Substances 0.000 claims description 5
- 235000010419 agar Nutrition 0.000 claims description 5
- 229940023476 agar Drugs 0.000 claims description 5
- 239000001110 calcium chloride Substances 0.000 claims description 5
- 229910001628 calcium chloride Inorganic materials 0.000 claims description 5
- 235000010418 carrageenan Nutrition 0.000 claims description 5
- 239000000679 carrageenan Substances 0.000 claims description 5
- 229920001525 carrageenan Polymers 0.000 claims description 5
- 229940113118 carrageenan Drugs 0.000 claims description 5
- 239000008273 gelatin Substances 0.000 claims description 5
- 229940014259 gelatin Drugs 0.000 claims description 5
- 229920000159 gelatin Polymers 0.000 claims description 5
- 235000019322 gelatine Nutrition 0.000 claims description 5
- 235000011852 gelatine desserts Nutrition 0.000 claims description 5
- 235000010493 xanthan gum Nutrition 0.000 claims description 5
- 239000000230 xanthan gum Substances 0.000 claims description 5
- 229920001285 xanthan gum Polymers 0.000 claims description 5
- 229940082509 xanthan gum Drugs 0.000 claims description 5
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 claims description 5
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 claims description 4
- 108010039918 Polylysine Proteins 0.000 claims description 4
- 229920002385 Sodium hyaluronate Polymers 0.000 claims description 4
- 229920000656 polylysine Polymers 0.000 claims description 4
- 235000010413 sodium alginate Nutrition 0.000 claims description 4
- 239000000661 sodium alginate Substances 0.000 claims description 4
- 229940005550 sodium alginate Drugs 0.000 claims description 4
- 229940010747 sodium hyaluronate Drugs 0.000 claims description 4
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 claims description 4
- 206010039085 Rhinitis allergic Diseases 0.000 claims description 2
- 201000010105 allergic rhinitis Diseases 0.000 claims description 2
- 208000030880 Nose disease Diseases 0.000 claims 2
- QQCBOIWDENXRLP-BYZMTCBYSA-N (8s,9s,10r,13r,14s,17s)-17-ethyl-10,13-dimethyl-6,7,8,9,11,12,14,15,16,17-decahydro-3h-cyclopenta[a]phenanthrene Chemical compound C1CC2=CCC=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](CC)[C@@]1(C)CC2 QQCBOIWDENXRLP-BYZMTCBYSA-N 0.000 claims 1
- 208000026344 Nasal disease Diseases 0.000 claims 1
- 208000030533 eye disease Diseases 0.000 claims 1
- 239000000203 mixture Substances 0.000 description 16
- 239000007864 aqueous solution Substances 0.000 description 15
- 229940079593 drug Drugs 0.000 description 14
- 239000000243 solution Substances 0.000 description 13
- 238000004659 sterilization and disinfection Methods 0.000 description 13
- 238000004132 cross linking Methods 0.000 description 11
- 238000002360 preparation method Methods 0.000 description 11
- 238000000034 method Methods 0.000 description 10
- 239000003755 preservative agent Substances 0.000 description 10
- 238000003756 stirring Methods 0.000 description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 10
- 239000000080 wetting agent Substances 0.000 description 7
- 239000006185 dispersion Substances 0.000 description 6
- 239000008213 purified water Substances 0.000 description 6
- 229910052739 hydrogen Inorganic materials 0.000 description 5
- 239000001257 hydrogen Substances 0.000 description 5
- 239000002270 dispersing agent Substances 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 150000003839 salts Chemical class 0.000 description 4
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 230000000052 comparative effect Effects 0.000 description 3
- 238000001879 gelation Methods 0.000 description 3
- 230000002209 hydrophobic effect Effects 0.000 description 3
- 230000007774 longterm Effects 0.000 description 3
- 210000004400 mucous membrane Anatomy 0.000 description 3
- 238000005191 phase separation Methods 0.000 description 3
- 229920000642 polymer Polymers 0.000 description 3
- 230000005855 radiation Effects 0.000 description 3
- 238000010008 shearing Methods 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- 239000013522 chelant Substances 0.000 description 2
- 229920001577 copolymer Polymers 0.000 description 2
- 239000003889 eye drop Substances 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000013355 food flavoring agent Nutrition 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 230000007794 irritation Effects 0.000 description 2
- 210000004877 mucosa Anatomy 0.000 description 2
- 239000007923 nasal drop Substances 0.000 description 2
- 229920001495 poly(sodium acrylate) polymer Polymers 0.000 description 2
- 229920000053 polysorbate 80 Polymers 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- NNMHYFLPFNGQFZ-UHFFFAOYSA-M sodium polyacrylate Chemical compound [Na+].[O-]C(=O)C=C NNMHYFLPFNGQFZ-UHFFFAOYSA-M 0.000 description 2
- 239000012453 solvate Substances 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 description 1
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 229920001661 Chitosan Polymers 0.000 description 1
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 description 1
- QIEPWCSVQYUPIY-LEKSSAKUSA-N Delta(1)-progesterone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 QIEPWCSVQYUPIY-LEKSSAKUSA-N 0.000 description 1
- 208000003556 Dry Eye Syndromes Diseases 0.000 description 1
- 206010013774 Dry eye Diseases 0.000 description 1
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 229920002873 Polyethylenimine Polymers 0.000 description 1
- 108010020346 Polyglutamic Acid Proteins 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 125000005907 alkyl ester group Chemical group 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 229940012356 eye drops Drugs 0.000 description 1
- 229920000370 gamma-poly(glutamate) polymer Polymers 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229940075529 glyceryl stearate Drugs 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 229940041616 menthol Drugs 0.000 description 1
- XJRBAMWJDBPFIM-UHFFFAOYSA-N methyl vinyl ether Chemical compound COC=C XJRBAMWJDBPFIM-UHFFFAOYSA-N 0.000 description 1
- 239000000693 micelle Substances 0.000 description 1
- 229940100662 nasal drops Drugs 0.000 description 1
- 239000002736 nonionic surfactant Substances 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 229960000292 pectin Drugs 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 239000004584 polyacrylic acid Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 229940068984 polyvinyl alcohol Drugs 0.000 description 1
- 235000019422 polyvinyl alcohol Nutrition 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 229940083542 sodium Drugs 0.000 description 1
- 235000015424 sodium Nutrition 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 229940037001 sodium edetate Drugs 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- WTWSHHITWMVLBX-DKWTVANSSA-M sodium;(2s)-2-aminobutanedioate;hydron Chemical compound [Na+].[O-]C(=O)[C@@H](N)CC(O)=O WTWSHHITWMVLBX-DKWTVANSSA-M 0.000 description 1
- 150000005846 sugar alcohols Polymers 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000009974 thixotropic effect Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 235000010384 tocopherol Nutrition 0.000 description 1
- 229960001295 tocopherol Drugs 0.000 description 1
- 229930003799 tocopherol Natural products 0.000 description 1
- 239000011732 tocopherol Substances 0.000 description 1
- 239000012929 tonicity agent Substances 0.000 description 1
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Inorganic Chemistry (AREA)
- Otolaryngology (AREA)
- Engineering & Computer Science (AREA)
- Ophthalmology & Optometry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Immunology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Emulsifying, Dispersing, Foam-Producing Or Wetting Agents (AREA)
Description
ジェランガム0.4部を精製水199.6部に溶解し、0.2%ジェランガム水溶液を調製した。得られた0.2%ジェランガム水溶液をせん断速度200/sで10分前処理し、2時間静置した。次いで粘度をレオメータ(TAインスツルメント社製、AR−200)を用い、せん断速度14.2/sで、温度25℃下で測定したところ、5mPa・sであり、その溶液は0.22μmのフィルターを用いて容易にろ過滅菌することができた。0.2%ジェランガム水溶液200部を90℃で攪拌しながら、0.22μmのフィルターでろ過滅菌した400mM塩化カルシウム水溶液1.5部を加え、ホモミキサーで12000rpm、30分攪拌しながら室温まで冷却し、無菌性ミクロゲルを調製した。得られたミクロゲルの粘度をレオメーターで測定したところ、137mPa・sであり、そのミクロゲルが薬物を長期間均一分散させるための適度な粘度を有していることが確認された。
0.2%ジェランガム水溶液200部を90℃で攪拌しながら、400mM塩化カルシウム水溶液1.5部を加え、得られた混合物をホモミキサーで12000rpm、30分攪拌しながら室温まで冷却し、ミクロゲルを調製した。カルメロースナトリウム0.8部を精製水19.2部に加え溶解させた後、得られた溶液にシクレソニド0.11部を加えてプロペラミキサーで予備分散したのち、得られた分散液をミクロゲル溶液に添加し、得られた混合物をホモミキサーで10000rpm、10分攪拌して水性懸濁液を得た。
表1に示す配合組成に変え、水溶性のイオン性ポリマー水溶液を用いないで、シクレソニドをミクロゲルに直接加え、湿潤剤を含まないミクロゲル単独の水性懸濁液とした以外は、実施例1と同様にして水性懸濁液を得た。表1に示すように、ミクロゲル単独の水性懸濁液では、シクレソニドの容器への著しい付着が観察された。
表1に示す配合組成に変えた以外は実施例1と同様にして水性懸濁液を得た。
Claims (8)
- シクレソニド、ならびにミクロゲル及び水溶性のイオン性ポリマーを含有する無菌性水性懸濁液であって、
ミクロゲルが、ジェランガム、カラギーナン、アルギン酸ナトリウム、寒天、キサンタンガム、及びゼラチンからなる群から選ばれる水溶性ポリマーの、非共有結合による分子間結合で得られたものである無菌性水性懸濁液。 - さらに、多価イオンを含有する請求項1記載の無菌性水性懸濁液。
- 多価イオンが、塩化カルシウムである請求項2記載の無菌性水性懸濁液。
- 水溶性のイオン性ポリマーが、カルメロースナトリウム、ヒアルロン酸ナトリウム、及びポリリジンからなる群から選ばれる少なくとも1種である請求項1から3までのいずれか1項に記載の無菌性水性懸濁液。
- シクレソニドが化合物[11β,16α(R)]−16,17−[(シクロヘキシルメチレン)ビス(オキシ)]−11−ヒドロキシ−21−(2−メチル−1−オキソプロポキシ)プレグナ−1,4−ジエン−3,20−ジオンである請求項1から4までのいずれか1項に記載の無菌性水性懸濁液。
- 請求項1から5までのいずれか1項に記載の無菌性水性懸濁液の製造方法において、
i)ミクロゲル形成可能な水溶性ポリマー溶液をろ過滅菌した後、ミクロゲルを形成させる工程、
ii)シクレソニドをろ過滅菌されたイオン性ポリマー水溶液に予備分散する工程、
iii)ミクロゲルと、シクレソニドを予備分散させたイオン性ポリマー水溶液とを混合する工程
を含む製造方法。 - 請求項1から5までのいずれか1項に記載の無菌性水性懸濁液を、鼻疾患もしくは眼疾患の治療用の医薬品の製造において用いる使用。
- 鼻疾患がアレルギー性鼻炎である請求項7に記載の使用。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2009525822A JP5550339B2 (ja) | 2006-12-27 | 2007-12-26 | シクレソニドを含有する無菌性水性懸濁液 |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2006351766 | 2006-12-27 | ||
JP2006351766 | 2006-12-27 | ||
JP2009525822A JP5550339B2 (ja) | 2006-12-27 | 2007-12-26 | シクレソニドを含有する無菌性水性懸濁液 |
PCT/JP2007/075396 WO2008078842A1 (en) | 2006-12-27 | 2007-12-26 | Ciclesonide containing sterile aqueous suspension |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2010514671A JP2010514671A (ja) | 2010-05-06 |
JP5550339B2 true JP5550339B2 (ja) | 2014-07-16 |
Family
ID=39156078
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2007332157A Expired - Fee Related JP5661985B2 (ja) | 2006-12-27 | 2007-12-25 | 無菌性水性懸濁製剤 |
JP2009525822A Active JP5550339B2 (ja) | 2006-12-27 | 2007-12-26 | シクレソニドを含有する無菌性水性懸濁液 |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2007332157A Expired - Fee Related JP5661985B2 (ja) | 2006-12-27 | 2007-12-25 | 無菌性水性懸濁製剤 |
Country Status (6)
Country | Link |
---|---|
US (1) | US8481516B2 (ja) |
EP (1) | EP2124881B1 (ja) |
JP (2) | JP5661985B2 (ja) |
AU (1) | AU2007339169B2 (ja) |
CA (1) | CA2673627A1 (ja) |
WO (1) | WO2008078842A1 (ja) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP5661985B2 (ja) * | 2006-12-27 | 2015-01-28 | 帝人ファーマ株式会社 | 無菌性水性懸濁製剤 |
ES2471145T3 (es) * | 2009-03-09 | 2014-06-25 | Mikasa Seiyaku Co,. Ltd. | Compuesto esteroide |
WO2011135585A2 (en) * | 2010-04-28 | 2011-11-03 | Cadila Healthcare Limited | Aqueous pharmaceutical solution of ciclesonide |
JP6828427B2 (ja) * | 2015-12-28 | 2021-02-10 | ライオン株式会社 | 眼科用組成物及びその製造方法 |
JP7106852B2 (ja) * | 2016-12-20 | 2022-07-27 | 大正製薬株式会社 | 懸濁型外用液剤 |
GB201820021D0 (en) * | 2018-12-07 | 2019-01-23 | Univ Birmingham | Ocular hydrogel compositions |
GB201820018D0 (en) * | 2018-12-07 | 2019-01-23 | Univ Birmingham | Therapeutic hydrogel compositions |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3962430A (en) | 1974-08-07 | 1976-06-08 | Merck & Co., Inc. | Sterilization of solid non-electrolyte medicinal agents employing sodium chloride |
GB8911177D0 (en) * | 1989-05-16 | 1989-07-05 | Vilain Jean | Alginate gel pharmaceutical product |
GB2291348B (en) | 1994-07-18 | 1999-01-20 | Johnson & Johnson Medical | Sterile gel composition for wound treatment comprising alginate and polyhydric alcohol |
JP3269770B2 (ja) | 1995-03-02 | 2002-04-02 | 参天製薬株式会社 | 再分散性の優れたイオン性高分子配合水性懸濁点眼剤 |
JPH10287552A (ja) * | 1997-04-11 | 1998-10-27 | Kobayashi Seiyaku Kogyo Kk | 滅菌されたアシクロビル水性懸濁点眼剤及びその製造方法 |
JP2000247887A (ja) * | 1999-03-01 | 2000-09-12 | Senju Pharmaceut Co Ltd | 水性懸濁液剤およびその製造方法 |
AR026073A1 (es) * | 1999-10-20 | 2002-12-26 | Nycomed Gmbh | Composicion farmaceutica acuosa que contiene ciclesonida |
JP2002284926A (ja) * | 2001-03-26 | 2002-10-03 | Noevir Co Ltd | マイクロゲル及びその調製方法、並びに増粘剤及び増粘性組成物 |
JP2002356419A (ja) * | 2001-03-29 | 2002-12-13 | Takeda Chem Ind Ltd | 微粒薬物の製造法 |
BRPI0312377A8 (pt) | 2002-07-02 | 2015-12-15 | Altana Pharma Ag | Suspensão aquosa estéril contendo ciclesonida |
US6698523B2 (en) * | 2002-07-02 | 2004-03-02 | Husco International, Inc. | Electrohydraulic control system for implement lift cylinders |
US20040023935A1 (en) * | 2002-08-02 | 2004-02-05 | Dey, L.P. | Inhalation compositions, methods of use thereof, and process for preparation of same |
PL373433A1 (en) * | 2002-08-30 | 2005-08-22 | Altana Pharma Ag | The use of the combination of ciclesonide and antihistamines for the treatment of allergic rhinitis |
EP1796679A1 (en) * | 2004-09-10 | 2007-06-20 | Altana Pharma AG | Ciclesonide and syk inhibitor combination and methods of use thereof |
JP5661985B2 (ja) * | 2006-12-27 | 2015-01-28 | 帝人ファーマ株式会社 | 無菌性水性懸濁製剤 |
-
2007
- 2007-12-25 JP JP2007332157A patent/JP5661985B2/ja not_active Expired - Fee Related
- 2007-12-26 US US12/448,351 patent/US8481516B2/en active Active
- 2007-12-26 AU AU2007339169A patent/AU2007339169B2/en active Active
- 2007-12-26 JP JP2009525822A patent/JP5550339B2/ja active Active
- 2007-12-26 WO PCT/JP2007/075396 patent/WO2008078842A1/en active Application Filing
- 2007-12-26 CA CA002673627A patent/CA2673627A1/en not_active Abandoned
- 2007-12-26 EP EP07860591.2A patent/EP2124881B1/en active Active
Also Published As
Publication number | Publication date |
---|---|
JP5661985B2 (ja) | 2015-01-28 |
JP2010514671A (ja) | 2010-05-06 |
WO2008078842A1 (en) | 2008-07-03 |
EP2124881B1 (en) | 2014-07-16 |
US20100009951A1 (en) | 2010-01-14 |
AU2007339169B2 (en) | 2013-09-26 |
EP2124881A1 (en) | 2009-12-02 |
JP2008179623A (ja) | 2008-08-07 |
US8481516B2 (en) | 2013-07-09 |
CA2673627A1 (en) | 2008-07-03 |
AU2007339169A1 (en) | 2008-07-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5550339B2 (ja) | シクレソニドを含有する無菌性水性懸濁液 | |
JP4934587B2 (ja) | 点眼用レバミピド結晶の水性懸濁溶液 | |
CN104350063B (zh) | 疏水性治疗剂的制剂、其制备方法及应用 | |
JP3903061B2 (ja) | 薬物を含有するナノ粒子およびその製造方法、ならびに当該ナノ粒子からなる非経口投与用製剤 | |
TWI415629B (zh) | 含有瑞巴匹特之水性醫藥懸浮物及其製造方法 | |
JP6101332B2 (ja) | レバミピドを含有する口腔内疾患治療用医薬組成物 | |
JP6856525B2 (ja) | グルココルチコステロイドのナノ微粒子を含有する水性懸濁液剤 | |
WO2010041684A1 (ja) | タクロリムス外用剤 | |
JP5203355B2 (ja) | 懸濁性ハイドロゲルとその製造方法 | |
EP1227817B1 (en) | Ciclesonide-containing aqueous pharmaceutical composition | |
CN109481403A (zh) | 一种壳聚糖修饰的醋酸曲安奈德脂质体及制备方法 | |
CA3145055A1 (en) | Process for the preparation of sterile ophthalmic aqueous fluticasone propionate form a nanocrystals suspensions | |
TWI707684B (zh) | 點眼用懸濁製劑 | |
EP3386483A1 (en) | Sterile parenteral suspensions | |
AU2018266131B2 (en) | Formulation of nanostructured gels for increased agent loading and adhesion | |
JP7106852B2 (ja) | 懸濁型外用液剤 | |
JP2004035441A (ja) | 無菌水性懸濁製剤 | |
CN115837027A (zh) | 一种眼用地塞米松药物组合物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20101007 |
|
RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20101228 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20130215 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20130501 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20130510 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20130807 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20131209 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20140421 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20140520 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 5550339 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
S111 | Request for change of ownership or part of ownership |
Free format text: JAPANESE INTERMEDIATE CODE: R313111 |
|
R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
S111 | Request for change of ownership or part of ownership |
Free format text: JAPANESE INTERMEDIATE CODE: R313113 |
|
R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
S111 | Request for change of ownership or part of ownership |
Free format text: JAPANESE INTERMEDIATE CODE: R313113 |
|
R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |